pneumonia. Pneumonia due to inhalation of vomit and gastric secretions
Conditions
Interventions
Intervention 1: Intervention group: patient receives metoclopramide 10 milligram -three times a day for 5 days.first dose prescribe in form of ampul and should be used from intravenous route.the other
Sponsors
Islamic Azad University of Pharmaceutical Science
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: dysphagia following the loss of consciousness,in ICU patients. Nasogastric tube requirement, more than 24 hours.
Exclusion criteria
Exclusion criteria: oesophageal disorder signs and symptoms of pneumonia pregnancy and lactation histoy of Parkinson disease contraindication of metoclopramide drug interaction with metoclopramide gastrointestinal disorders like:GI bleeding ,obstruction ,cancer and perforation . gastrointestinal surgery. presence of pheochromocytoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cough incidence. Timepoint: before intervention, day 1,3 and5. Method of measurement: observational information and nursing records.;Tachypnoea (respiratory rate >25 per minute). Timepoint: before intervention, day 1,3 and5. Method of measurement: assessment of vital signs and nursing records.;- Sputum production or oropharyngeal secretions. Timepoint: before intervention, day 1,3 and5. Method of measurement: assessment of clinical situation and nursing records.;-Hypoxia (oxygen saturation =90% ). Timepoint: before intervention, day 1,3 and5. Method of measurement: puls oximeter.;-New abnormal breathing sounds in chest examination. Timepoint: before intervention, day 1,3 and5. Method of measurement: chest physical examination by stethoscope.;Fever >38 degree celsius. Timepoint: before intervention, day 1,3 and5. Method of measurement: termometer.;Leucocytosis (WBC >11 000 per Mililiter). Timepoint: before intervention, day 1,3 and5. Method of measurement: complete blood count.;Abnormal elevation of erythrocyte sedimentation rate. Timepoint: before intervention, day 1and5. Method of measurement: erythrocyte sedimentation rate test.;New chest Radiological shadowing. Timepoint: before intervention, day 3 and 5. Method of measurement: chest x ray radiography.;Leucopoenia (WBC < 3000 per Mililiter). Timepoint: before intervention, day 1,3 and5. Method of measurement: complete blood count.;Abnormal elevation of c reactive protein. Timepoint: before intervention, day 1 and 5. Method of measurement: c reactive protein test.;Symptom complex of sweating, rigors, fever, and aches and pains. Timepoint: before intervention, day 1,3 and5. Method of measurement: observational information,thermometer and critical care pain observation tool. | — |
Secondary
| Measure | Time frame |
|---|---|
| Counting the days that paitient stays in intensive care unit. Timepoint: from the first day of study to last day of staying patient in the intensive care unit. Method of measurement: assessment of the patients medical records.;Number of antibiotic therapy days. Timepoint: from the first day of study to last day of staying patient in the intensive care unit. Method of measurement: assessment of the patients medical records.;Highest white blood cells count in millimeter cube. Timepoint: daily from the first day to 5th day. Method of measurement: complete blood count.;Highest C reactive protein( milligram per deciliter). Timepoint: first day and 5th day of study. Method of measurement: c reactive protein assessment test.;Lowest oxygen saturation percent. Timepoint: daily from the first day to 5th day of study. Method of measurement: puls oxymeter.;Mortality at 30 days. Timepoint: from the first day of study to 30th day. Method of measurement: assessment of medical records.;Regurgitation through Nasogastric tube. Timepoint: daily from the first day to 5th day of study. Method of measurement: observational assessment of patients situation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMehdi Rajabi
Islamic Azad University
Outcome results
None listed